TXG possible reversalOversold on the daily, Filled Gap from Nov 2023, Risk is todays low 35.42. Rsi curl .
PT is open, had previous support at 40.40 which would be 1st resistance , SMA or fib levels also
−2.18USD
−255.10 MUSD
618.73 MUSD
98.01 M
About 10x Genomics, Inc.
Sector
Industry
CEO
Serge Saxonov
Website
Headquarters
Pleasanton
Employees (FY)
1.26 K
Founded
2012
ISIN
US88025U1097
FIGI
BBG007WX14X0
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
TXG approaching support zonesAnticipating support in these zones wont hurt. Keeping strict stop loss and following long trade has a higher probability to win
Best stock to buy nowBest stock to buy now - 23.05.2023
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genom
TXG Healthcare name we are shortA small position is suggested due to our stance on Healthcare being bullish and also the R isn't quite at 2.00 as of yet.
10X Genomics, Inc - Bullish divergenceOn the above 6-day chart price action has corrected 75% since the sell signal back in November 2020. A number of reasons now exist to be long, including:
1) Double ‘incredible buy’ signals. Awesome.
2) Price action and RSI resistance breakouts.
3) Price action is arrested by past support / resist
14/4/2022 NASDAQ (TXG)Short (Entry Price) within the sell zone area and exit (Stop Loss) above the red line. Can take profit at the suggested Target Price.
Entry Price: $68.33 / $70.99
Target Price: $65.60 / $69.04
Stop Loss: $72.94
10x Genomics (NASDAQ: $TXG) Looks Ready For Growth! 🍄10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluid
TXG for an oversold bounceLong TXG 2,000 shares and 51 $110 Feb 18th calls. There has been some interesting call option activity on TXG as of last week 1/25/2022 someone purchased 600 Feb 18, 2022 $110 calls and 600 Feb 18, 2022 $120 calls and paid approximately $400k for these call options for a stock with little option ac
$TXG Double Bottom Setup$TXG working on a well defined double bottom base.
2 things grabbed my attention that made me pause while flipping through charts:
* Vol dry up while rounding up that 2nd bottom
* Pretty much pocket pivot after pocket pivot through out the rally from 2nd bottom(aggressive buying)
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TXG is 32.86 USD — it has decreased by 4.89% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange 10x Genomics, Inc. stocks are traded under the ticker TXG.
10x Genomics, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for 10x Genomics, Inc. has a max estimate of 70.00 USD and a min estimate of 30.00 USD.
TXG earnings for the last quarter are −0.79 USD whereas the estimation was −0.46 USD which accounts for −71.58% surprise. Estimated earnings for the next quarter are −0.35 USD. See more details about 10x Genomics, Inc. earnings.
10x Genomics, Inc. revenue for the last quarter amounts to 153.64 M USD despite the estimated figure of 151.30 M USD. In the next quarter revenue is expected to reach 182.73 M USD.
Yes, you can track 10x Genomics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, TXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 10x Genomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 1.26 K employees. See our rating of the largest employees — is 10x Genomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 10x Genomics, Inc. EBITDA is −160.73 M USD, and current EBITDA margin is −25.58%. See more stats in 10x Genomics, Inc. financial statements.